130 related articles for article (PubMed ID: 21397718)
21. A novel gamma radiation-inactivated sabin-based polio vaccine.
Tobin GJ; Tobin JK; Gaidamakova EK; Wiggins TJ; Bushnell RV; Lee WM; Matrosova VY; Dollery SJ; Meeks HN; Kouiavskaia D; Chumakov K; Daly MJ
PLoS One; 2020; 15(1):e0228006. PubMed ID: 31999745
[TBL] [Abstract][Full Text] [Related]
22. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
23. Measuring Poliovirus Antigenicity by Surface Plasmon Resonance. Application for Potency Indicating Assays.
Westdijk J; van der Maas L; Ten Have R; Kersten G
Methods Mol Biol; 2016; 1387():299-323. PubMed ID: 26983742
[TBL] [Abstract][Full Text] [Related]
24. Development of inactivated poliovirus vaccine from Sabin strains: A progress report.
Okayasu H; Sein C; Hamidi A; Bakker WA; Sutter RW
Biologicals; 2016 Nov; 44(6):581-587. PubMed ID: 27720268
[TBL] [Abstract][Full Text] [Related]
25. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
28. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
29. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
[TBL] [Abstract][Full Text] [Related]
30. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Schild GC
Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
[TBL] [Abstract][Full Text] [Related]
31. A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing.
Bockstal V; Sanders B; Achterberg R; Tiemessen M; Bogaert L; Van der Meer M; Schuitemaker H; Zahn R
Vaccine; 2018 May; 36(21):2917-2920. PubMed ID: 29685598
[TBL] [Abstract][Full Text] [Related]
32. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
33. Regulation and standardization of IPV and IPV combination vaccines.
Baca-Estrada M; Griffiths E
Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
[TBL] [Abstract][Full Text] [Related]
34. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses.
Muller DA; Pearson FE; Fernando GJ; Agyei-Yeboah C; Owens NS; Corrie SR; Crichton ML; Wei JC; Weldon WC; Oberste MS; Young PR; Kendall MA
Sci Rep; 2016 Feb; 6():22094. PubMed ID: 26911254
[TBL] [Abstract][Full Text] [Related]
35. [The effect of aluminum adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine].
Wang F; Zhang M; Xie BF; Cao H; Tong SY; Wang JR; Yu XP; Tang Y; Yang JR; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):102-4. PubMed ID: 24044212
[TBL] [Abstract][Full Text] [Related]
36. Determination of antigenic properties of vaccine derived poliovirus strains.
Pliaka V; Achilleos C; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonica C; Levidiotou-Stefanou S; Markoulatos P
Vaccine; 2010 Dec; 29(1):26-33. PubMed ID: 20974307
[TBL] [Abstract][Full Text] [Related]
37. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
[TBL] [Abstract][Full Text] [Related]
38. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
39. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
Rezapkin G; Dragunsky E; Chumakov K
Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
[TBL] [Abstract][Full Text] [Related]
40. Structural studies of virus-antibody immune complexes (poliovirus type I): Characterization of the epitopes in 3D.
Bannwarth L; Girerd-Chambaz Y; Arteni AA; Guigner JM; Lemains J; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Feb; 63(2):279-86. PubMed ID: 25146483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
